Meth withdrawl
Pro Research Analysisby 
Searched over 200M research papers for "meth withdrawl"
Understanding Methamphetamine Withdrawal: Symptoms, Mechanisms, and Potential Treatments
Methamphetamine Withdrawal Symptoms and Prevalence
Anxiety and Depression During Methamphetamine Withdrawal
Methamphetamine (Meth) withdrawal is often accompanied by significant anxiety and depression, which are major public health concerns. Studies have shown that anxiety-like behaviors are prevalent during Meth withdrawal, with a strong correlation to the medial prefrontal cortex (mPFC)1. Depression is also a core symptom, particularly during the first several weeks of abstinence, and is associated with increased levels of brain-derived neurotrophic factor (BDNF) in the nucleus accumbens (NAc)4. In a study of Han Chinese Meth users, 64.6% reported depressive symptoms during early withdrawal, with higher frequency of drug use and history of relapse being significant risk factors3.
Neurochemical Changes During Withdrawal
Meth withdrawal induces significant neurochemical changes in the brain. For instance, alterations in neurometabolites such as myo-inositol and glutamine in the anterior cingulate cortex and caudate-putamen have been observed, which tend to normalize after prolonged abstinence5. Additionally, serum BDNF levels are significantly reduced during early withdrawal, indicating impaired neuroprotective functions10.
Mechanisms Underlying Methamphetamine Withdrawal Symptoms
GABAergic and BDNF-TrkB Signaling Pathways
The GABAergic interneuron-pyramidal neuron pathway in the mPFC plays a crucial role in Meth withdrawal-induced anxiety. Gegen-Qinlian decoction (GQD), a traditional Chinese medicine, has been shown to alleviate anxiety by restoring this pathway and regulating the MAPK signaling pathway in the mPFC1. Similarly, increased BDNF-TrkB signaling in the NAc shell is implicated in depression-like behaviors during withdrawal, with TrkB antagonists showing potential therapeutic effects4.
Stress and Sympathetic Activation
Meth withdrawal activates the brain's stress system, particularly corticotropin-releasing factor (CRF) neurons in the hypothalamus and bed nucleus of the stria terminalis (BNST), which are associated with cardiac sympathetic control. This activation is paralleled by increased activity in cardiac sympathetic pathways, suggesting a link between Meth withdrawal and cardiovascular risks8. Additionally, changes in the μ-opioid receptor (MOPr), oxytocin receptor (OTR), and CRF systems are associated with anxiety-related symptoms during withdrawal9.
Potential Treatments for Methamphetamine Withdrawal
Pharmacological Interventions
Despite extensive research, no medication has been conclusively approved for Meth withdrawal. A systematic review of randomized controlled trials (RCTs) found that amineptine may reduce discontinuation rates and improve global state, but no other medications showed significant efficacy compared to placebo2.
Traditional and Novel Therapeutics
Gegen-Qinlian decoction (GQD) has shown promise in alleviating Meth withdrawal anxiety by targeting specific neural pathways and gene expressions in the mPFC1. Metformin has demonstrated antidepressant effects by improving oxidative stress biomarkers and neuronal damage in the hippocampus, suggesting its potential as a therapeutic option6. Similarly, selegiline has been found to reverse depressive-like behaviors and prevent mitochondrial dysfunction during Meth withdrawal7.
Conclusion
Methamphetamine withdrawal is characterized by significant anxiety and depression, driven by complex neurochemical and neurobiological changes. While traditional pharmacological treatments have shown limited efficacy, alternative therapies such as GQD, metformin, and selegiline offer promising avenues for alleviating withdrawal symptoms. Further research is needed to develop effective treatments and improve the quality of life for individuals undergoing Meth withdrawal.
Sources and full results
Most relevant research papers on this topic
Gegen‐Qinlian decoction—A traditional Chinese medicine formula—Alleviates methamphetamine withdrawal induced anxiety by targeting GABAergic interneuron‐pyramidal neuron pathway in mPFC
Gegen-Qinlian decoction effectively alleviates meth withdrawal anxiety by targeting the GABA IN-PN pathway and regulating the local GABA IN-PN pathway in the mPFC.
Non-RCT
Animal StudyPharmacological treatment for methamphetamine withdrawal: A systematic review and meta‐analysis of randomised controlled trials
There is insufficient evidence to indicate any medication is effective for methamphetamine withdrawal, with a need for better powered, high-quality trials.
Meta-AnalysisPrevalence and correlates of depressive symptoms during early methamphetamine withdrawal in Han Chinese population.
Depressive symptoms are common during early methamphetamine withdrawal, with risk factors including frequency of use and history of relapse, while moderate alcohol consumption reduces the risk.
Observational StudyBDNF–TrkB signaling in the nucleus accumbens shell of mice has key role in methamphetamine withdrawal symptoms
Increased BDNF-TrkB signaling in the nucleus accumbens shell plays a key role in methamphetamine withdrawal symptoms, and TrkB antagonists show potential therapeutic benefits for these symptoms in METH abusers.
Non-RCTAnimal Study
Very Rigorous Journal
Highly CitedWithdrawal from long‐term methamphetamine self‐administration ‘normalizes’ neurometabolites in rhesus monkeys: a 1H MR spectroscopy study
Long-term methamphetamine self-administration in rhesus monkeys leads to neurochemical changes that normalize after prolonged abstinence, suggesting therapeutic effects of long-term drug withdrawal.
Non-RCTAnimal Study
Rigorous JournalMetformin attenuates depressive-like behaviour of methamphetamine withdrawal in mice: A mechanistic approach
Metformin can reduce depressive-like behavior and improve brain function in mice with methamphetamine withdrawal syndrome, offering a potential new treatment option.
RCTAnimal StudySelegiline alleviates the depressive-like behaviors of methamphetamine withdrawal syndrome through modulating mitochondrial function and energy hemostasis
Selegiline effectively reduces depressive-like behaviors and prevents mitochondrial dysfunction in male mice after methamphetamine withdrawal.
RCTAnimal StudyMethamphetamine withdrawal induces activation of CRF neurons in the brain stress system in parallel with an increased activity of cardiac sympathetic pathways
Chronic methamphetamine administration and withdrawal activate brain stress systems and increase cardiac sympathetic pathway activity, contributing to the increased cardiovascular risk associated with METH use.
Non-RCTAnimal StudyMethamphetamine abstinence induces changes in μ-opioid receptor, oxytocin and CRF systems: Association with an anxiogenic phenotype
Chronic methamphetamine use and withdrawal can induce brain-region specific neuroadaptations, potentially explaining the anxiety-related symptoms and psychomotor sensitization during withdrawal.
Non-RCTAnimal StudyRigorous JournalSerum brain‐derived neurotrophic factor levels were reduced during methamphetamine early withdrawal
Methamphetamine early withdrawal leads to significantly lower serum BDNF levels, suggesting severe BDNF dysfunction and impaired neuroprotective function after repetitive misuse.
Non-RCT